Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SonoScape Medical Corp. (300633.SZ)
Shenzhen, CN
SonoScape Medical Corp. is engaged in the global development and production of medical devices, originating from its base in China. Its comprehensive portfolio includes a diverse range of ultrasound diagnostic systems, encompassing cart-based color Doppler, handheld color Doppler, black and white ultrasound units, and specialized veterinary ultrasound apparatus. The company further provides endoscopy solutions, such as sophisticated image processing equipment, illumination tools, and products tailored for gastroenterological examinations. Beyond its hardware offerings, SonoScape extends crucial support services, including expert technical assistance, component provision, educational programs, system upgrades, and direct field intervention. Established in 2002, SonoScape Medical Corp. maintains its corporate headquarters in Shenzhen, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.26% | -0.41% | -8.98% | -9.70% | -17.60% | -9.08% | -27.72% | -56.87% | -15.33% | +218.99% | +218.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | -2 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+14.7% ★ Q1'26: +11.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+39.4% ★ Q1'26: -245.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-9.3% Q1'26: -36.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+7.3% ★ Q1'26: -4.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+8.9% ★ Q1'26: -2.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.09× ★ Q1'26: -3.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 7 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
719.36M
est: 719.00M (+0.0%)
|
989.07M
est: 906.40M (+9.1%)
|
1.23B
est: 1.23B (-0.3%)
|
1.25B
est: 1.32B (-5.0%)
|
1.16B
est: 1.22B (-4.6%)
|
1.44B
est: 1.49B (-3.1%)
|
1.76B
est: 1.81B (-2.5%)
|
2.12B
est: 2.09B (+1.5%)
|
2.01B
est: 2.02B (-0.2%)
|
2.31B
est: 2.23B (+3.6%)
|
2.63B
2.62B – 2.64B
+18.2% YoY
|
3.01B
2.85B – 3.15B
+14.3% YoY
|
3.47B
3.42B – 3.53B
+15.3% YoY
|
| EBITDA |
90.26M
est: 121.06M (-25.4%)
|
199.76M
est: 152.62M (+30.9%)
|
269.32M
est: 207.27M (+29.9%)
|
122.22M
est: 222.26M (-45.0%)
|
171.25M
est: 205.24M (-16.6%)
|
247.77M
est: 251.05M (-1.3%)
|
356.61M
est: 304.43M (+17.1%)
|
507.71M
est: 339.38M (+49.6%)
|
163.86M
est: 327.65M (-50.0%)
|
271.09M
est: 361.83M (-25.1%)
|
427.77M
426.08M – 429.45M
+18.2% YoY
|
489.07M
462.94M – 512.32M
+14.3% YoY
|
563.85M
554.82M – 572.89M
+15.3% YoY
|
| EBIT |
74.13M
est: 103.56M (-28.4%)
|
184.66M
est: 130.55M (+41.4%)
|
250.12M
est: 177.31M (+41.1%)
|
97.36M
est: 190.13M (-48.8%)
|
142.37M
est: 175.57M (-18.9%)
|
216.21M
est: 214.76M (+0.7%)
|
320.99M
est: 260.42M (+23.3%)
|
457.68M
est: 280.29M (+63.3%)
|
100.97M
est: 270.60M (-62.7%)
|
168.35M
est: 298.84M (-43.7%)
|
353.29M
351.90M – 354.68M
+18.2% YoY
|
403.92M
382.34M – 423.12M
+14.3% YoY
|
465.69M
458.22M – 473.15M
+15.3% YoY
|
| Net Income |
130.43M
est: 137.54M (-5.2%)
|
190.02M
est: 184.82M (+2.8%)
|
252.62M
est: 277.24M (-8.9%)
|
101.54M
est: 133.24M (-23.8%)
|
-46.26M
est: 107.46M (-143.1%)
|
247.24M
est: 225.66M (+9.6%)
|
369.81M
est: 358.08M (+3.3%)
|
454.44M
est: 351.95M (+29.1%)
|
142.40M
est: 189.10M (-24.7%)
|
197.28M
est: 177.60M (+11.1%)
|
340.66M
323.41M – 357.90M
+91.8% YoY
|
442.41M
432.96M – 469.04M
+29.9% YoY
|
480.79M
452.01M – 509.57M
+8.7% YoY
|
| SGA |
372.08M
est: 229.97M (+61.8%)
|
323.72M
est: 289.90M (+11.7%)
|
413.20M
est: 393.72M (+4.9%)
|
480.33M
est: 422.19M (+13.8%)
|
399.54M
est: 389.85M (+2.5%)
|
457.37M
est: 476.88M (-4.1%)
|
521.16M
est: 578.28M (-9.9%)
|
616.63M
est: 576.18M (+7.0%)
|
710.04M
est: 556.26M (+27.6%)
|
283.97M
est: 614.30M (-53.8%)
|
726.23M
723.38M – 729.09M
+18.2% YoY
|
830.30M
785.94M – 869.78M
+14.3% YoY
|
957.28M
941.93M – 972.62M
+15.3% YoY
|
| EPS |
0.36
est: 0.32 (+12.5%)
|
0.49
est: 0.43 (+14.0%)
|
0.63
est: 0.65 (-2.3%)
|
0.25
est: 0.31 (-18.1%)
|
-0.12
est: 0.25 (-146.2%)
|
0.62
est: 0.53 (+18.1%)
|
0.86
est: 0.83 (+3.2%)
|
1.06
est: 0.82 (+29.6%)
|
0.33
est: 0.44 (-25.1%)
|
0.46
est: 0.40 (+13.8%)
|
0.79
0.75 – 0.83
+96.0% YoY
|
1.04
1.01 – 1.09
+31.5% YoY
|
1.10
1.05 – 1.19
+5.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.01% | 44.0K | 0.59% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 320.9K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.4K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 23.5K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.16M | 0.06% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 52.9K | 0.29% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 39.7K | 0.28% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.30M | 0.05% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 13.1K | 0.10% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 87.0K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Li | Board Secretary & Deputy GM | — | male |
| Kunxiang Wu | GM & Director | — | male |
| Nai Zhang Feng | Deputy GM & Director | — | — |
| Xiang Li | Deputy General Manager | — | — |
| Yibo Huang | Deputy GM & Director | — | male |
| Yuezuo Luo | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300633.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
